COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience
نویسندگان
چکیده
منابع مشابه
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
INTRODUCTION Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system leading to progressive neurodegeneration and disability. Until 2010, all approved disease-modifying drugs for MS required parenteral administration, which is associated with suboptimal adherence. It was anticipated that new approaches to treatment, including oral agents such as cladribine ta...
متن کاملSafety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of D...
متن کاملAlteration of OGG1, MYH and MTH1 genes expression in relapsing-remitting multiple sclerosis patients
Introduction: Previous studies revealed that oxidative stress is elevated in multiple sclerosis (MS). It can harm to biological macromolecules such as DNA. However, the molecular mechanism in protection of genetic information from DNA damages is not clear in MS disease. In this study the expression level of some important genes of OGG1 and MYH involved in base excision repair pathway and, MTH1 ...
متن کاملPotential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including IFN β-1a administered intramuscularly or subcutaneously and IFN β-1b subcutaneously, glatiramer acetate, natalizumab, and mitoxantrone are approved disease-modifying therapies for the treatment of relapsing...
متن کاملIncreased Expression of miR-202-3p in Patients with Relapsing-Remitting Multiple Sclerosis
Background and objectives: One of the latest studies in the genetics field is the evaluation of role of micro-RNAs as a biomarker for diagnosis of multiple sclerosis (MS), which is a demyelinating disease of the central nervous system (CNS) and emerges in the form of numerous small and large plaques in white matter in the brain and spinal cord. This disease could be associated with several comp...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neurology
سال: 2020
ISSN: 0340-5354,1432-1459
DOI: 10.1007/s00415-020-10309-4